Clinical Trials Browser

Brain Neoplasms

Carcinoma, Non-Small-Cell Lung

Anatomic Stage III Breast Cancer AJCC v8

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Polycystic Ovary Syndrome

Breast Neoplasms, Breast Neoplasms, Male

Advanced Breast Cancer

Breast Neoplasms

Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

Breast Neoplasms

Breast Neoplasms

Anatomic Stage II Breast Cancer AJCC v8

Breast Neoplasms

Locoregional Recurrence

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Breast Neoplasms

HR+/HER2- Breast Cancer

Advanced Unresectable or Metastatic Breast Cancer of Adults

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Low Grade Serous Ovarian Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Endometrial Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

HR+/HER2- Breast Cancer

Fallopian Tube Neoplasms, Ovarian Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Cancer Female

Carcinoma, Intraductal, Noninfiltrating

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Endometrial Neoplasms

Clinical Trials

Study of Letrozole in Recurrent Gliomas

KAT6

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

OPERA-02

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

DEBRA

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

PHACS

OXYTAM

MIRHO

A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS

Adjuvant WIDER

EvoPAR-BR01

TAILORx

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

PF-07104091 as a Single Agent and in Combination Therapy

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

CAMBRIA-1

OMAHA-015

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

RaPhLRR

LaPemERLA

INAVO123

AVZO-023-1001

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

ADEPT

Roll-over Study to Allow Continued Access to Ribociclib

EMBER-4

RAMP 301

SIE-3

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

EndoMAP

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Letrozole After Tamoxifen in Treating Women With Breast Cancer

PIKASSO-01

ELEGANT

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

MNEMOSYNE

NeoMARS

Morpheus-panBC

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

I-SPY

OPERA-01

FEMUS